Heart Failure
Canagliflozin improves HF symptoms: CHIEF-HF
The SGLT2 inhibitor canagliflozin improved HF symptoms within 3 months in patients with HF, regardless of ejection fraction or diabetes status, according to results of the fully remote CHIEF-HF trial.
Empagliflozin yields clinical benefit in patients hospitalized with acute HF: EMPULSE
In the EMPULSE trial, adults hospitalized with acute HF who received the SGLT2 inhibitor empagliflozin were 36% more likely than those on placebo to have clinical benefit at 90 days, including prevention of death and readmissions.
In HF, link between economic distress, poor outcomes varies by race, ethnicity
In patients with HF, the relationship between community-level economic distress and adverse clinical outcomes varies by race and ethnicity, according to findings presented at the American Heart Association Scientific Sessions.
Incidence of cardiac amyloidosis on the rise, mortality improving
The incidence of cardiac amyloidosis in the Danish population increased in the last 2 decades, translating to a potential increase in the global population, according to research published in JACC: CardioOncology.
Lower ambulatory hemodynamic pressure correlates with improved HF symptom burden
Lower mean diastolic pulmonary artery pressure was associated with improvements in HF symptoms among participants in the EMBRACE-HF trial, researchers reported.
GUIDE-HF: Benefit of hemodynamic guided-management in HF similar across EF
Device therapy for pulmonary artery-pressure-guided management of patients with HF was beneficial regardless of ejection fraction, according to new data from the GUIDE-HF trial presented at TCT 2021.
New data show empagliflozin slows GFR, maintains ejection fraction in CKD, heart failure
Study measures discrimination in models that predict heart failure in patients with CKD
Blood pressure control may lower the risk of heart failure in patients with CKD
Data presented at virtual 2021 ASN Kidney Week suggests “intensive blood pressure control” may reduce the risk of heart failure in patients with chronic kidney disease.
GALACTIC-HF: Omecamtiv mecarbil effective in patients with severe HF
In a post hoc analysis of the GALACTIC-HF trial, omecamtiv mecarbil reduced the primary endpoint of time to first HF event or CV death among patients with severe HF.